PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Transl Lung Cancer Res
.
2018 Sep;7(Suppl 3):S287-S289.
doi: 10.21037/tlcr.2018.07.09.
Authors
Alfredo Addeo
1
,
Giuseppe Luigi Banna
2
Affiliations
1
Oncology Department, University Hospital Geneva, Geneva, Switzerland.
2
Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.
PMID:
30393624
PMCID:
PMC6193904
DOI:
10.21037/tlcr.2018.07.09
No abstract available
Publication types
Editorial